Roche licenses Hanmi Pharm's non-incretin obesity drug HM17321 in a deal worth up to $2.3B, including $190M upfront.
Roche is spending $190 million upfront to license a non-incretin obesity drug from South Korea’s Hanmi Pharm.
The deal represents the latest in a string …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Roche commits to lean-mass preservation with Hanmi obesity deal
Hanmi Pharm signs $2.3 bil. licensing deal with Roche's Genentech for obesity drug candidate - The Korea Times
Hanmi signs record $2.3b obesity drug deal with Genentech
Roche snags rights to South Korean obesity treatment
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
Hanmi dispara 30% após acordo de US$ 2,31 bi com subsidiária da Roche para tratamento de obesidade
Hanmi Pharm in spotlight as Korea's 1st obesity drug nears launch - The Korea Times
Roche earmarks $750M to double the size of its Oregon manufacturing facility
For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that…
Hanmi Pharm, a Korean pharmaceutical company, said Monday it has signed a 3.2 trillion-won ($2.3 billion) licensing deal with…
Hanmi Pharmaceutical said Monday it has inked an exclusive licensing agreement with Genentech for its obesity drug candidate…
Roche subsidiary secures global rights to manufacture South Korean obesity treatment.
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
HM17321, da Hanmi, é um dos potenciais tratamentos de nova geração, já que está sendo desenvolvido como um medicamento projetado…
